title: The sub-chronic oral toxicity of dearomatized hydrocarbon solvents in Sprague-Dawley rats.
abstract: Dearomatized hydrocarbon solvents in the C9-C14 aliphatic carbon number range were developed as alternatives to traditional solvents such as mineral spirits, but with lower aromatic content. Previous subchronic toxicity studies (both published and unpublished) have shown minimal to no systemic effects with exposure to dearomatized solvents, with the exception of rat-specific renal effects that have no relevance to humans. In this study, Sprague-Dawley rats were exposed to 0, 500, 2500 and 5000mg/kg/day of a C10-C13 dearomatized solvent for 90days by oral gavage. Liver enlargement and centrilobular hypertrophy were observed in all treated groups but were considered adaptive consequences of hydrocarbon-induced microsomal enzyme induction. Clinical chemistry data showed elevations of alanine aminotransferase (ALT), gamma glutamyltransferase (GGT) and total bilirubin in mid (ALT alone) and high dose groups, suggesting potential hepatobiliary effects with high dose exposure. Increased absolute kidney weight changes were restricted to male rats and associated with renal lesions indicative of alpha-2u globulin-mediated nephropathy. One limitation of the NOAEL/LOAEL approach in selecting points of departure for exposure limits is its dependence on dose selection/study design. Hence, a more robust approach that incorporates all data points on the dose-response curve, such as bench mark modeling, is preferred. Overall, benchmark dose analysis estimated a BMDL of 1857mg/kg/day based on increased serum ALT. This value is consistent with studies of similar hydrocarbon substances showing a lack of systemic effects at doses up to 1000mg/kg/day in the same rat strain.
authors.affiliation: ExxonMobil Biomedical Sciences, Inc., 1545 Route 22 E., Annandale, NJ 08801, USA. Electronic address: moyinoluwa.d.adenuga@exxonmobil.com.
authors.forename: David
authors.initials: D
authors.lastname: Adenuga
authors.affiliation: Shell Health, Shell International B.V., P.O. Box 162, 2501 AN The Hague, The Netherlands.
authors.forename: Juan-Carlos
authors.initials: JC
authors.lastname: Carrillo
authors.affiliation: ExxonMobil Biomedical Sciences, Inc., 1545 Route 22 E., Annandale, NJ 08801, USA.
authors.forename: Richard H
authors.initials: RH
authors.lastname: Mckee
mesh_terms: D000284:Administration, Oral; D000410:Alanine Transaminase / Q000097:blood; D000510:Alpha-Globulins / Q000378:metabolism; D000818:Animals; D001835:Body Weight / Q000187:drug effects; D002780:Cholestasis, Intrahepatic / Q000139:chemically induced; D004305:Dose-Response Relationship, Drug; D005260:Female; D006838:Hydrocarbons / Q000633:toxicity*; D007668:Kidney / Q000187:drug effects / Q000378:metabolism / Q000473:pathology; D008099:Liver / Q000187:drug effects / Q000473:pathology; D008297:Male; D019055:No-Observed-Adverse-Effect Level; D017207:Rats, Sprague-Dawley; D012997:Solvents / Q000633:toxicity*; D059550:Toxicity Tests, Subchronic; D005723:gamma-Glutamyltransferase / Q000097:blood
chemical_list: D000510:Alpha-Globulins; D006838:Hydrocarbons; D012997:Solvents; C013803:alpha 2u globulin; D005723:gamma-Glutamyltransferase; D000410:Alanine Transaminase
keywords: Cholestasis; Dearomatized hydrocarbon solvent; Hydrocarbon solvent; Isoalkane; Isoparaffin; Oral toxicity; Subchronic toxicity; UVCB